Company Profiles

driven by the PitchBook Platform

TheraVasc

Description

Developer of therapies and treatments for chronic medical diseases. The company's first product is TV1001, an oral formulation of sodium nitrite to treat PAD (Peripheral Artery Disease) and to determine safety and blood levels of the drug, targeting patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease.

2009

Founded

PRIVATE

Status

Later Stage VC

Latest Deal Type

$4.24M

Total Amount Raised

11

Investors

Description

Developer of therapies and treatments for chronic medical diseases. The company's first product is TV1001, an oral formulation of sodium nitrite to treat PAD (Peripheral Artery Disease) and to determine safety and blood levels of the drug, targeting patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease.

Website:

www.theravasc.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals

Primary Office

10000 Cedar Avenue MS Suite 1 Cleveland, OH 44106United States +1 (318) 349-3851
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore TheraVasc's full profile, request a free trial.

    TheraVasc Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    TheraVasc Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    TheraVasc Investors (11)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Global Cardiovascular Innovation CenterAccelerator/IncubatorMinority000 0000000 0000
    Great Lakes Innovation and Development EnterpriseAccelerator/IncubatorMinority000 0000000 0000
    Innovation Fund of Northeast OhioAccelerator/IncubatorMinority000 0000000 0000
    JumpStartAccelerator/IncubatorMinority000 0000000 0000
    North Coast Angel FundAngel GroupMinority000 0000000 0000
    Global Cardiovascular Innovation Center Accelerator/Incubator
    Great Lakes Innovation and Development Enterprise Accelerator/Incubator
    Innovation Fund of Northeast Ohio Accelerator/Incubator
    JumpStart Accelerator/Incubator
    North Coast Angel Fund Angel Group

    TheraVasc Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Chris Kevil Ph.DCo-Founder, Chief Scientific Advisor & Chief Scientific Officer
    Douglas Flanagan Ph.DChief Formulation Advisor
    Anthony Giordano Ph.DCo-Founder, Chief Executive Officer, Board Member and President
    Chris Kevil Ph.D Co-Founder, Chief Scientific Advisor & Chief Scientific Officer
    Douglas Flanagan Ph.D Chief Formulation Advisor
    Anthony Giordano Ph.D Co-Founder, Chief Executive Officer, Board Member and President

    TheraVasc Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Amol SoinTheraVascChief Medical Officer, Chief Clinical Advisor & Board Member000 0000
    Anthony Giordano Ph.DSelfCo-Founder, Chief Executive Officer, Board Member and President000 0000
    John HustonOhio Tech AngelsCo-Founder000 0000
    Kyle Chan Ph.DSelfBoard Member000 0000
    Susan LuriaSelfBoard Member000 0000
    Amol Soin Chief Medical Officer, Chief Clinical Advisor & Board Member TheraVasc
    Anthony Giordano Ph.D Co-Founder, Chief Executive Officer, Board Member and President Self
    John Huston Co-Founder Ohio Tech Angels
    Kyle Chan Ph.D Board Member Self
    Susan Luria Board Member Self
    Request full access to PitchBook